Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 2, 2012, Pages 135-144

  Mishra, Alita ^a   Younossi, Zobair M ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

NAFLD; NASH

Indexed keywords

CHOLESTEROL;

AGE DISTRIBUTION; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ETHNICITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RACE; RISK FACTOR; SEX DIFFERENCE; SLEEP APNEA SYNDROME; SURVIVAL RATE; SURVIVAL TIME;

EID: 84864076332     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60102-9     Document Type: Article

References (89)

1. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Asia-Pacific Working Party on NAFLD. J Gastroenterol Hepatol 2007, 22:778.
2. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
3. American Gastroenterological Association (AGA) medical position Statement Non-alcoholic fatty liver disease. Gastroenterology 2002, 123:1702-1704.
4. Whalley S, Puvanachandra P, Desia A, Kennedy H Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007, 7:119-124.
5. Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005, 41:64-71.
6. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005, 143:722-728.
7. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
8. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009, 50:797-804.
9. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007, 47:239-244.
10. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000, 69:2410-2415.
11. Ong JP, Younossi ZM Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007, 11:1-16.
12. Kopec KL, Burns D Nonalcoholic fatty liver disease. a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011, 26:565-576.
13. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005, 15:310-315.
14. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007, 13:1579-1584.
15. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012.
16. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical Gastroenterol Hepatol 2011, 9:524-530.
17. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005, 43:508-514.
18. Ruhl CE, Everhart JE Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124:71-79.
19. Frith J, Day CP, Henderson E, Burt AD, Newton JL Non-alcoholic fatty liver disease in older people. Gerontology 2009, 55:607-613.
20. Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007, 22:1482-1489.
21. Ong JP, Pitts A, Younossi ZM Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49:608-612.
22. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1224-1229.
23. Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int 2004, 24:588-594.
24. Vernon G, Baranova A, Younossi ZM Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
25. Reid A Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
26. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008, 9:616-622.
27. Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006, 16:1351.
28. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124.
29. Wagenknecht LE, Scherzinger AL, Stamm ER, et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009, 17:1240-1246.
30. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
31. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
32. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010, 285:6706-6715.
33. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362:1082-1089.
34. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011, 7:e1001324.
35. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009, 29:113-119.
36. Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009, 57:205-210.
37. Adams LA, Angulo P, Lindor KD Nonalcoholic fatty liver disease. CMAJ 2005, 172:899-905.
38. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004, 2:262-265.
39. Stepanova M, Rafiq N, Younossi ZM Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010, 59:1410-1415.
40. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
41. Angelico F, Del Ben M, Conti R, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003, 18:588-594.
42. Boza C, Riquelme A, Ibañez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005, 15:1148-1153.
43. Abrams GA, Kunde SS, Lazenby AJ, Clements RH Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004, 40:475-483.
44. Machado M, Marques-Vidal P, Cortez-Pinto H Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
45. Colicchio P, Tarantino G, del Genio F, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005, 49:289-295.
46. Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003, 138:1240-1244.
47. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
48. Dolce CJ, Russo M, Keller JE, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis 2009, 5:323-328.
49. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408.
50. Harnois F, Msika S, Sabaté JM, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 2006, 16:183-188.
51. Spaulding L, Trainer T, Janiec D Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg 2003, 13:347-349.
52. Farrell GC, Larter CZ Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:s99-s112.
53. Ehrmann DA Polycystic ovary syndrome. N Engl J Med 2005, 352:1223-1236.
54. Setji TL, Brown AJ Polycystic ovary syndrome: diagnosis and treatment. Am J Med 2007, 120:128-132.
55. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006, 91:4842-4848.
56. Cerda C, Perez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007, 47:412-417.
57. Hossain N, Stepanova M, Afendy A, et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011, 46:479-484.
58. Ahmed MH, Byrne CD Obstructive sleep apnea syndrome and fatty liver: association or causal link?. World J Gastroenterol 2010, 16:4243-4252.
59. Vgontzas AN, Bixler EO, Chrousos GP Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005, 9:211-224.
60. Keijer J, van Schothorst EM Adipose tissue failure and mitochondria as a possible target for improvement by bioactive food components. Curr Opin Lipidol 2008, 19:4-10.
61. Mishra P, Nugent C, Afendy A, et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 2008, 28:1080-1086.
62. Requarth JA, Burchard KW, Colacchio TA, et al. Long term morbidity following jejunoileal bypass: the continuing potential need for surgical reversal. Arch Surg 1995, 130:318-325.
63. Grundy SM, Brewere HB, Celleman JI, Smith SC, Lenfant C Definition of metabolic syndrome: report of the National Heart Lung and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004, 109:433-438.
64. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
65. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28 year follow-up. Hepatology 2010, 51:595-602.
66. Musso G, Gambino R, Cassader M, Pagano G Meta-analysis: natural history of non-alcoholic fatty liver disease and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
67. Lebovics E, Rubin J Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev 2011, 27:419-424.
68. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011, 35:23-28.
69. Hernaez R Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2011, [Epub ahead of print].
70. Ludwig J, Viggiano TR, McGill DB, Oh BJ Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
71. Teli MR, James OF, Burt AD, Bennett MK, Day CP The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
72. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
73. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011, 53:1874-1882.
74. Lee RG Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989, 20:594-598.
75. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
76. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51:371-379.
77. Harrison SA, Torgerson S, Hayashi PH The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042-2047.
78. Sanyal AJ, Banas C, Sargent C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
79. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
80. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma is obesity-related cryptogenic cirrhosis. Hepatology 2002, 35:1485-1493.
81. Bruix J, Sherman M Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
82. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastoenterol Hepatol 2009, 24:248-254.
83. Bhagat V, Mindikoglu AL, Nudo CG, et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009, 15:1814-1820.
84. Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic liver disease. Liver Transpl 2010, 16:431-439.
85. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30:2119-2121.
86. Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of Type II diabetes in Korean adults. Diabetes Med 2008, 25:476-481.
87. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health check-up. J Gastroenterol Hepatol 2010, 25:352-356.
88. Silverman EM, Sapala JA, Appelman HD Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995, 104:23-31.
89. Mottin CC, Moretto M, Padoin AV, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight lass induced by bariatric surgery. Obes Surg 2005, 15:788-793.